13 January 2012 - UK's National Institute for Health and Clinical Excellence (NICE) today confirmed in a final draft guidance its initial draft recommendation for the use of Eli Lilly & Co's (NYSE: LLY) Bydureon prolonged release exenatide in triple therapy regimens for treatment of Type 2 diabetes.

Final guidance is expected to be published next month.

The guidance covers a therapy combination with metformin, sulphonylureas and thiazolidinediones, which are currently used to address Type 2 diabetes by lowering the glucose levels in the blood.

The current guidance concerns only the prolonged release suspension, which is injected once weekly compared to twice a day for the conventional formulation of exenatide.

Bydureon belongs to the glucagon-like peptide-1 (GLP-1) receptor agonist class of drugs.